AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford purchased 1,365 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was bought at an average cost of $13.10 per share, for a total transaction of $17,881.50. Following the completion of the transaction, the director now owns 25,098 shares in the company, valued at $328,783.80. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

AXGN stock traded up $0.51 during midday trading on Tuesday, hitting $15.12. The company’s stock had a trading volume of 20,318 shares, compared to its average volume of 765,664. The stock has a market capitalization of $525.23 million, a P/E ratio of -28.00 and a beta of 0.18. AxoGen, Inc has a 12 month low of $11.82 and a 12 month high of $46.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.87 and a current ratio of 8.70. The business has a 50-day simple moving average of $18.42.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The business had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $26.77 million. AxoGen had a negative return on equity of 16.73% and a negative net margin of 26.91%. The firm’s quarterly revenue was up 29.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.09) EPS. On average, equities analysts predict that AxoGen, Inc will post -0.71 earnings per share for the current year.

AXGN has been the topic of a number of analyst reports. BidaskClub cut AxoGen from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 24th. William Blair cut AxoGen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Canaccord Genuity set a $30.00 price objective on AxoGen and gave the company a “buy” rating in a research report on Wednesday, August 7th. BTIG Research lowered their price objective on AxoGen to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald lowered their price objective on AxoGen from $30.00 to $21.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $31.00.

Hedge funds have recently added to or reduced their stakes in the stock. Quantamental Technologies LLC lifted its position in AxoGen by 108.3% in the 1st quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 744 shares in the last quarter. Cutler Group LP lifted its holdings in shares of AxoGen by 120.0% during the 1st quarter. Cutler Group LP now owns 2,200 shares of the medical equipment provider’s stock valued at $46,000 after buying an additional 1,200 shares during the period. Advisor Group Inc. lifted its holdings in shares of AxoGen by 86.3% during the 2nd quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 1,180 shares during the period. Aperio Group LLC bought a new position in shares of AxoGen during the 2nd quarter valued at $77,000. Finally, Bank of Montreal Can lifted its holdings in shares of AxoGen by 82.6% during the 2nd quarter. Bank of Montreal Can now owns 6,595 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 2,984 shares during the period. 87.46% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.